Longeveron to Present at H.C. Wainwright 26th Annual Global Investment Conference

Longeveron Inc. (NASDAQ: LGVN), a biotechnology company specializing in regenerative medicine, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, in New York City. The company will present on Tuesday, September 10, 2024, from 5:00 to 5:30 p.m. ET. The conference presentation will be webcast and accessible through the "Events and Presentations" section of Longeveron's website. Additionally, a replay of the webcast will be available on the website for 180 days following the event.

Longeveron Inc. is a clinical-stage biotechnology company that focuses on developing regenerative medicinal therapies aimed at addressing unmet medical needs. The company's leading investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B™ showcases multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects. These mechanisms present broad potential applications across various disease areas.

Currently, Longeveron is developing Lomecel-B™ for three primary indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. The development programs for Lomecel-B™ have garnered significant recognition and support from the U.S. Food and Drug Administration (FDA), earning five distinct designations. For the HLHS program, the product has received Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation. For the AD program, Lomecel-B™ has been awarded Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Longeveron continues to advance its research and development efforts to bring innovative therapies to patients with serious health conditions. By leveraging the unique properties of Lomecel-B™, the company aims to address the substantial unmet needs in treating HLHS, AD, and Aging-related Frailty. The regenerative and reparative effects of Lomecel-B™ hold promise for improving patient outcomes and quality of life across these challenging medical areas.

The announcement of Longeveron's participation in the upcoming H.C. Wainwright Global Investment Conference reflects the company's commitment to engaging with the investment community and sharing updates on its progress and future plans. This event provides an opportunity for stakeholders to gain insights into Longeveron's clinical programs, regulatory achievements, and strategic direction.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!